CRISPR/Cas9 delivery by NIR-responsive biomimetic nanoparticles for targeted HBV therapy

BACKGROUND: Currently, there are no curative drugs for hepatitis B virus (HBV). Complete elimination of HBV covalently closed circular DNA (cccDNA) is key to the complete cure of hepatitis B virus infection. The CRISPR/Cas9 system can directly destroy HBV cccDNA. However, a CRISPR/Cas9 delivery syst...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Dan, Chen, Ling, Li, Chengbi, Long, Quanxin, Yang, Qing, Huang, Ailong, Tang, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740473/
https://www.ncbi.nlm.nih.gov/pubmed/34991617
http://dx.doi.org/10.1186/s12951-021-01233-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740473/
https://www.ncbi.nlm.nih.gov/pubmed/34991617
http://dx.doi.org/10.1186/s12951-021-01233-4

Ejemplares similares